Boston Keratoprosthesis type 1 (KPro) without contact lens wearing in end-stage corneal disease: The APEC experience.

Guillermo De Wit-CarterCésar Hernández-Chavarría Pedro-Ivan Navarro-Naranjo Cristal Manzanillo-RosarioRicardo Navarro-SaucedoAna Mercedes García-AlbisuaEverardo Hernandez-QuintelaEmmanuel Cabrera-MartínezGabriela Ordoñez-RanzValeria Sanchez-Huerta

Published in: European journal of ophthalmology (2023)

We report the results of a retrospective cohort of twenty-three eyes (22 patients) who were implanted with a Boston type 1 KPro without contact lens wearing to treat corneal blindness. BSCVA improved significantly in most patients achieving 20/200 or better at the 2-year follow-up. Retention rate was 87%, with the presence of RPM as the most common complication.

Keyphrases

cataract surgery
optical coherence tomography
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes